HIV-1 p17 Antibody (17-1): sc-69723

HIV-1 p17 Antibody (17-1) is a mouse monoclonal IgG2b kappa light chain antibody that detects HIV-1 p17 of HIV-1 origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Anti-HIV-1 p17 antibody (17-1) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. HIV-1 p17 functions as a crucial structural matrix protein with a significant role in viral life cycle, particularly in assembly and release of new virions. Located at the inner surface of viral envelope, HIV-1 p17 maintains viral core stability and facilitates transport of viral nucleocapsids from nucleus to plasma membrane, where viral assembly occurs. This process ensures efficient release of newly formed viral particles to infect other cells. Anti-HIV-1 p17 antibodies serve as serological markers for disease progression, highlighting HIV-1 p17′s potential as a target for therapeutic interventions and immunizations against HIV-1.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HIV-1 p17 Antibody (17-1) References:

1. Immunodominant epitopes of HIV-1 p17 and p24.  |  Graham, S., et al. 1992. AIDS Res Hum Retroviruses. 8: 1781-8. PMID: 1280955
2. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection.  |  Jiang, JD., et al. 1992. J Acquir Immune Defic Syndr (1988). 5: 382-90. PMID: 1372353
3. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.  |  Fiorentini, S., et al. 2004. Biopolymers. 76: 334-43. PMID: 15386266
4. Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30.  |  Boucher, CA., et al. 1990. J Clin Lab Anal. 4: 43-7. PMID: 1690277
5. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells.  |  Giagulli, C., et al. 2011. PLoS One. 6: e17831. PMID: 21423810
6. B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.  |  Giagulli, C., et al. 2021. Cancer Gene Ther. 28: 649-666. PMID: 33093643
7. HIV-1 p17 matrix protein enhances type I interferon responses through the p17-OLA1-STING axis.  |  Zhang, L., et al. 2024. J Cell Sci. 137: PMID: 38132845
8. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.  |  Sarin, PS., et al. 1995. Cell Mol Biol (Noisy-le-grand). 41: 401-7. PMID: 7580834
9. A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.  |  Chargelegue, D., et al. 1993. Clin Exp Immunol. 93: 331-6. PMID: 8370162
10. [HIV-1 p17 matrix protein is transported into the cell nucleus and binds with genomic viral RNA].  |  Bukrinskaia, AG., et al. 1993. Mol Biol (Mosk). 27: 49-57. PMID: 8483474
11. Antibodies to the HIV-1 p17 protein cross-react with human superoxide dismutase-2.  |  Kato, T., et al. 1997. Biochem Biophys Res Commun. 230: 184-7. PMID: 9020042
12. Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity.  |  Birk, M., et al. 1998. AIDS. 12: 1973-81. PMID: 9814865

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-HIV-1 p17 Antibody (17-1) has 2 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

HIV-1 p17 Antibody (17-1) Specifications

Alternate Product Name: HIV-1 p17

Product Clone Name: 17-1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids:

Epitope Target: HIV-1 p17

Epitope Species: HIV-1

Product Reactivity/Detection: Gag p17

Species Reactivity/Detection: HIV-1

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, FCM

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for HIV-1 p17 Antibody (17-1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin